Healthcare services group Uniphar said its business continued to grow in 2024, with organic growth as all its divisions.
In a trading update for the year ended 31 December 2024, Uniphar said it performed in line with expectations for earnings per share. Organic gross profit rose more than 8 per cent, while adjusted earnings per share growth was 12 per cent.
Looking ahead, Uniphar said it was well-positioned to deliver organic gross profit growth across all divisions and expects double digit growth in its pharma division, and single digit in medtech, and supply chain and retail.
“2024 was a great year for Uniphar, with all our divisions contributing to excellent organic growth,” said Uniphar group chief executive Ger Rabbette. “The results show the positive impact that our strategy is having on our ability to grow at pace organically. We have now delivered a five-year EPS CAGR of over 15 per cent. Based on our 2024 results, we are even more confident of reaching our €200 million EBITDA target over the medium-term, with at least 80 per cent of our growth being organic.”
Uniphar said it expects to publish its final results for the year on February 25th.
- Sign up for the Business Today newsletter and get the latest business news and commentary in your inbox every weekday morning
- Opt in to Business push alerts and have the best news, analysis and comment delivered directly to your phone
- Join The Irish Times on WhatsApp and stay up to date
- Our Inside Business podcast is published weekly – Find the latest episode here
